MAP
NBIX icon

Moody Aldrich Partners’s Neurocrine Biosciences NBIX Stock Holding History

Moody Aldrich Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,863
Closed -$671K – 224
2024
Q1 		$671K Hold
4,863
– – 0.11% 127
2023
Q4 		$641K Hold
4,863
– – 0.12% 125
2023
Q3 		$547K Buy
+4,863
New +$512K 0.1% 127
2020
Q3 		– Sell
-1,683
Closed -$205K – 177
2020
Q2 		$205K Buy
+1,683
New +$186K 0.04% 157
2018
Q4 		– Sell
-1,725
Closed -$212K – 105
2018
Q3 		$212K Buy
+1,725
New +$196K 0.06% 102
2018
Q1 		– Sell
-2,702
Closed -$210K – 94
2017
Q4 		$210K Sell
2,702
-19,554
-88% -$1.33M 0.17% 88
2017
Q3 		$1.36M Buy
22,256
+2,591
+13% +$137K 1.4% 25
2017
Q2 		$905K Buy
19,665
+10,515
+115% +$510K 1.13% 36
2017
Q1 		$396K Sell
9,150
-15,245
-62% -$653K 0.68% 70
2016
Q4 		$944K Sell
24,395
-9,945
-29% -$450K 0.61% 70
2016
Q3 		$1.74M Buy
34,340
+3,380
+11% +$168K 1.21% 30
2016
Q2 		$1.41M Buy
30,960
+21,125
+215% +$973K 1.16% 33
2016
Q1 		$389K Buy
+9,835
New +$390K 0.82% 70

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Moody Aldrich Partners's NBIX Position: Q2 2024 in Review

Moody Aldrich Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 4,863 shares — an estimated $671K sold.

Moody Aldrich Partners first reported a position in NBIX in Q1 2016 and held it in 13 quarters. The position peaked at $1.74M in Q3 2016. 595 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Moody Aldrich Partners reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 4,863 Neurocrine Biosciences shares in Q2 2024, an estimated $671K.
  • Moody Aldrich Partners first reported a position in Neurocrine Biosciences in Q1 2016 and held it in 13 quarters.
  • Moody Aldrich Partners's Neurocrine Biosciences position peaked at $1.74M in Q3 2016.
  • 595 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.